Pasar al contenido principal

REGULADORES DE LA PLASTICIDAD DE MELANOMA

PID2019-106852RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuronal cannabinoid CB1 receptors suppress the growth of melanoma brain metastases by inhibiting glutamatergic signalling

  • Costas-Insua, Carlos
  • Seijo-Vila, Marta
  • Blázquez, Cristina
  • Blasco-Benito, Sandra
  • Rodríguez-Baena, Francisco Javier
  • Marsicano, Giovanni
  • Pérez-Gómez, Eduardo
  • Sánchez, Cristina
  • Sánchez-Laorden, Berta
  • Guzmán, Manuel
This article belongs to the Special Issue Novel Insights into Glioblastoma and Brain Metastases., [Simple Summary] An estimated 60% of melanoma patients develop melanoma brain metastases (MBMs). However, the molecular factors that govern the growth of MBMs are still unknown. The excitatory neurotransmitter glutamate has been shown to control the proliferation of various types of cancer cells within the brain parenchyma, but the cellular sources and molecular mechanisms involved in this process remain unclear. By their well-known role in inhibiting synaptic glutamate release, cannabinoid CB1 receptors (CB1Rs) located on glutamatergic nerve terminals are conceivably well-positioned to control the growth of MBMs. In silico data mining in cancer-genome atlases and in vitro studies with melanoma cell lines supported that a glutamate-NMDA receptor axis drives melanoma cell proliferation. Strikingly, grafting melanoma cells into the brain of mice lacking CB1Rs selectively in glutamatergic neurons increased tumour size and concomitantly activated NMDA receptors on tumour cells. Altogether, our findings reveal an unprecedented role of neuronal CB1Rs in controlling MBMs., Melanoma is one of the deadliest forms of cancer. Most melanoma deaths are caused by distant metastases in several organs, especially the brain, the so-called melanoma brain metastases (MBMs). However, the precise mechanisms that sustain the growth of MBMs remain elusive. Recently, the excitatory neurotransmitter glutamate has been proposed as a brain-specific, pro-tumorigenic signal for various types of cancers, but how neuronal glutamate shuttling onto metastases is regulated remains unknown. Here, we show that the cannabinoid CB1 receptor (CB1R), a master regulator of glutamate output from nerve terminals, controls MBM proliferation. First, in silico transcriptomic analysis of cancer-genome atlases indicated an aberrant expression of glutamate receptors in human metastatic melanoma samples. Second, in vitro experiments conducted on three different melanoma cell lines showed that the selective blockade of glutamatergic NMDA receptors, but not AMPA or metabotropic receptors, reduces cell proliferation. Third, in vivo grafting of melanoma cells in the brain of mice selectively devoid of CB1Rs in glutamatergic neurons increased tumour cell proliferation in concert with NMDA receptor activation, whereas melanoma cell growth in other tissue locations was not affected. Taken together, our findings demonstrate an unprecedented regulatory role of neuronal CB1Rs in the MBM tumour microenvironment., This research was funded by the Spanish Ministerio de Ciencia e Innovación (MICIN; supported with European Regional Development (FEDER) funds; grant numbers PID2021-125118OB-I00 to M.G., PID2019-106852RB-I00 to B.S.-L., and PI17/00041 and PI20/00590 to C.S. and E.P.-G.) and by Fundación Canna (grant number 2023/0036 to M.G.). G.M. was supported by INSERM. C.C.-I. was supported by a contract from the Spanish Ministerio de Universidades (Formación de Profesorado Universitario Program, reference FPU16/02593). M.S.-V. was supported by a contract from Universidad Complutense de Madrid (Contratos Predoctorales UCM Program)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

  • Redondo-Muñoz, Marta
  • Rodríguez-Baena, Francisco Javier
  • Matheu, Ander
  • Wellbrock, Claudia
  • Aznar Benitah, Salvador
  • Sánchez-Laorden, Berta
  • Arozarena, Imanol
Redondo-Muñoz, M., Rodriguez-Baena, F.J., Aldaz, P. et al., Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF inhibitor (BRAFi) treatment contributes to acquired therapy resistance in mice. Targeting FAO using the US Food and Drug Administration-approved and European Medicines Agency-approved anti-anginal drug ranolazine (RANO) delays tumour recurrence with acquired BRAFi resistance. Single-cell RNA-sequencing analysis reveals that RANO diminishes the abundance of the therapy-resistant NGFRhi neural crest stem cell subpopulation. Moreover, by rewiring the methionine salvage pathway, RANO enhances melanoma immunogenicity through increased antigen presentation and interferon signalling. Combination of RANO with anti-PD-L1 antibodies strongly improves survival by increasing antitumour immune responses. Altogether, we show that RANO increases the efficacy of targeted melanoma therapy through its effects on FAO and the methionine salvage pathway. Importantly, our study suggests that RANO could sensitize BRAFi-resistant tumours to immunotherapy. Since RANO has very mild side-effects, it might constitute a therapeutic option to improve the two main strategies currently used to treat metastatic melanoma., I.A., P.A., D.E. and A.M. acknowledge funding from the Ministry of Economy and Competitiveness (Institute of Health Carlos III; refs. PI19/00645 to I.A., PI16-01911 to I.A., CPII20/00011 to I.A., CD21/00137 to P.A., PI20/00010 to D.E., PI20/00419 to D.E, PI19/01355 to A.M.). I.A. is also funded by Departamento de Salud del Gobierno de Navarra, Spain (ref. G°Na 71/17) D.A. acknowledges funding from The Spanish Association against Cancer (AECC; PROYE16001ESCO), Biomedicine Project Grant from the Department of Health of the Government of Navarre-FEDER funds (BMED 050-2019, 51-2021) and Strategic projects from the Department of Industry, Government of Navarre (AGATA, ref. 0011-1411; LINTERNA, ref. 0011–1411; DESCARTHES, 0011-1411-2019-000058). M.R.-M. is funded by a PhD studentship from the Department of Industry of the Government of Navarra, Spain and by the Grupo Español Multidisciplinar de Melanoma. The University of Colorado School of Medicine Metabolomics Core is supported in part by the University of Colorado Cancer Center award from the National Cancer Institute P30CA046934. Research in the S.A.B. laboratory is supported partially by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 787041), the Government of Cataluña (SGR grant), the Government of Spain (MINECO), the La Marató/TV3 Foundation, the Foundation Lilliane Bettencourt, the Spanish Association for Cancer Research (AECC) and the Worldwide Cancer Research Foundation (WCRF). Work in the laboratory of B.S.-L. is supported by: PID2019-106852-RBI00 funded by MCIN/AEI/10.13039/501100011033, the Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.91574) and the FERO Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microenvironmental Snail1-induced immunosuppression promotes melanoma growth

  • Arumi-Planas, Marta
  • Rodríguez-Baena, Francisco Javier
  • Cabello-Torres, Francisco M.
  • Graciá Quiles, Francisco
  • López-Blau, Cristina
  • Nieto, M. Ángela
  • Sánchez-Laorden, Berta
Melanoma is an aggressive form of skin cancer due to its high metastatic abilities and resistance to therapies. Melanoma cells reside in a heterogeneous tumour microenvironment that acts as a crucial regulator of its progression. Snail1 is an epithelial-to-mesenchymal transition transcription factor expressed during development and reactivated in pathological situations including fibrosis and cancer. In this work, we show that Snail1 is activated in the melanoma microenvironment, particularly in fibroblasts. Analysis of mouse models that allow stromal Snail1 depletion and therapeutic Snail1 blockade indicate that targeting Snail1 in the tumour microenvironment decreases melanoma growth and lung metastatic burden, extending mice survival. Transcriptomic analysis of melanoma-associated fibroblasts and analysis of the tumours indicate that stromal Snail1 induces melanoma growth by promoting an immunosuppressive microenvironment and a decrease in anti-tumour immunity. This study unveils a novel role of Snail1 in melanoma biology and supports its potential as a therapeutic target., This work was supported by grants SAF2016-75702-R and PID2019-106852-RBI00 (to BS-L), RTI2018-096501-B-I00 and PID2021-125682NB-I00 (to MAN) funded by MCIN/AEI/ 10.13039/501100011033 and ERDF, the Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.91574 to B.S-L), the FERO Foundation (to B.S-L) and the AECC Scientific Foundation (FC_AECC PROYE19073NIE to MAN). MA-P and FC-T were recipients of a FPI predoctoral contract. FJR-B and FG hold contracts from the Generalitat Valenciana (APOSTD and ACIF, respectively). We also acknowledge financial support from the Spanish State Research Agency, through the ‘Severo Ochoa Programme’ for Centres of Excellence in R&D (SEV-2017-0273) and the Generalitat Valenciana through the ‘Prometeo Programme’ for Groups of Excellence (CIPROM/2021/045)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Schwann cells in regeneration and cancer: an epithelial-mesenchymal transition perspective

  • Graciá Quiles, Francisco
  • Sánchez-Laorden, Berta
  • Gómez-Sánchez, José A.
In the peripheral nervous system, glial cells, known as Schwann cells (SCs), are responsible for supporting and maintaining nerves. One of the most important characteristics of SCs is their remarkable plasticity. In various injury contexts, SCs undergo a reprogramming process that generates specialized cells to promote tissue regeneration and repair. However, in pathological conditions, this same plasticity and regenerative potential can be hijacked. Different studies highlight the activation of the epithelial-mesenchymal transition (EMT) as a driver of SC phenotypic plasticity. Although SCs are not epithelial, their neural crest origin makes EMT activation crucial for their ability to adopt repair phenotypes, mirroring the plasticity observed during development. These adaptive processes are essential for regeneration. However, EMT activation in SCs-derived tumours enhances cancer progression and aggressiveness. Furthermore, in the tumour microenvironment (TME), SCs also acquire activated phenotypes that contribute to tumour migration and invasion by activating EMT in cancer cells. In this review, we will discuss how EMT impacts SC plasticity and function from development and tissue regeneration to pathological conditions, such as cancer., This work was supported by a Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP22/00078 to J.A.G.-S.) and by the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033 and ERDF (PID2019-106852-RBI00 and PID2022-141613OB-I00 to B.S.-L. and PID2022-143269OB-I00 to J.A.G.-S.). We also acknowledge financial support from ISABIAL through a grant from Convocatoria Intramural 2024, the GVA through the ‘Prometeo Programme’ for Groups of Excellence (CIPROM/2021/045) and International Center for Ageing Research (ICAR) to B.S.-L., and Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033. Illustrations were created with BioRender., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed